Amgen has agreed to co-develop and co-commercialize with Kyowa Kirin its Phase III-bound KHK4083, a potentially first-in-class treatment for atopic dermatitis, through a collaboration that could generate more than $1.2 billion for the Japanese pharma—and expand its development into other autoimmune diseases. “Plans will be reviewed with global regulatory agencies later this year, with the […]

Big Danish biotech Genmab has signed on to a new collaboration, and it’s one both parties hope will tackle a broad swath of cancer indications. Genmab is partnering with Bolt Biotherapeutics out of Redwood City, CA, to develop up to three new antibody-based conjugates in oncology. In the deal, Genmab is paying Bolt $10 million […]

Genmab and Bolt Biotherapeutics have teamed up to develop bispecific immune-stimulating antibody conjugates (ISACs). The collaboration brings together Genmab’s bispecific capabilities with Bolt’s innate immune stimulant platform to create a new type of immuno-oncology drug. Bolt raised a $230 million IPO early this year on the strength of a platform and pipeline designed to overcome […]